Trioda Wilingi

About

Trioda Wilingi develops injectable medical gels made from spinifex-derived cellulose nanofibres for osteoarthritis, drug delivery and cosmetic uses, combining Traditional Owner knowledge with university research and Indigenous harvesting.

Mission

Trioda Wilingi holds exclusive global rights to develop novel injectable medical gels formulated from spinifex-derived cellulose nanofibres. The company’s core product targets applications including osteoarthritis treatment, drug delivery and cosmetic treatments. Early data indicate the spinifex gels last longer, are easier to inject and may be safer than current medical gel products. The underlying spinifex nanofibres are reported to be stronger, longer, thinner and more flexible than alternatives and are produced via a gentle, low‑impact nanotechnology process. Trioda Wilingi integrates Traditional Owner knowledge with university research and aims to create a new Australian industry majority owned by Indigenous Australians. Plans in the deal include Indigenous roles in harvesting and early processing, plus a portion of any future royalties allocated to an Indigenous education fund.

Quick Facts